Navidea Biopharmaceuticals (NAVB) Earnings Date, Estimates & Call Transcripts $0.0010 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share EarningsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrends Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNAVB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NAVB Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! Navidea Biopharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript11/14/2023Q3 2023-($0.02)($0.02)($0.02)--8/11/2023Q2 2023-($0.03)($0.03)($0.18)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)-- Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--5/11/2023Q1 2023-($0.05)($0.05)($0.05)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--3/21/2023Q4 2022-($0.11)($0.11)($0.11)--Collapse of the Petrodollar (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public.11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million11/14/2022Q3 2022-($0.25)($0.25)($0.25)-$0.01 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million8/15/2022Q2 2022-($0.10)($0.10)($0.10)-$0.06 million5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--Collapse of the Petrodollar (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public.5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--5/12/2022Q1 2022-($0.10)($0.10)($0.10)--3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million3/23/2022Q4 2021-($0.12)($0.12)($0.12)-$0.05 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021-($0.08)($0.08)($0.08)$0.60 million$0.10 million11/10/2021Q3 2021($0.11)($0.08)+$0.03($0.08)$0.60 million$0.10 million Alex's "Next Magnificent Seven" Stocks (Ad)Today Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now.8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/11/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million8/10/2021Q2 2021($0.09)($0.09)-($0.09)$0.60 million$0.26 million 5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/11/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million5/10/2021Q1 2021($0.08)($0.11)($0.03)($0.11)$0.60 million$0.12 million 3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/24/2021Q4 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.22 million3/23/2021Q4 2020($0.12)($0.11)+$0.01($0.11)$0.60 million$0.22 million 11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million11/12/2020Q3 2020($0.08)($0.13)($0.05)($0.13)$0.30 million$0.27 million 11/12/2020Q3($0.09)($0.13)($0.04)($0.13)$0.30 million$0.27 million 8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.10)($0.11)($0.01)($0.11)$0.60 million$0.27 million8/13/2020Q2 2020($0.12)($0.11)+$0.01($0.11)$0.60 million$0.27 million 5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million5/14/2020Q1 2020-($0.13)($0.13)($0.13)-$0.16 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million3/11/2020Q4 2019($0.12)($0.15)($0.03)($0.15)$0.30 million$0.12 million 11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3 2019-($0.17)($0.17)($0.17)-$0.24 million11/7/2019Q3($0.17)($0.17)-($0.17)-$0.24 million 8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019-($0.24)($0.24)($0.24)-$0.26 million8/8/2019Q2 2019($0.15)($0.24)($0.09)($0.24)-$0.26 million Navidea Biopharmaceuticals Earnings - Frequently Asked Questions How much revenue does Navidea Biopharmaceuticals generate each year? Navidea Biopharmaceuticals (NYSE:NAVB) has a recorded annual revenue of $70,000.00. How much profit does Navidea Biopharmaceuticals generate each year? Navidea Biopharmaceuticals (NYSE:NAVB) has a recorded net income of -$15.18 million. NAVB has generated -$0.06 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: IDXX Earnings Date LNTH Earnings Date NEOG Earnings Date CLDX Earnings Date QDEL Earnings Date NTLA Earnings Date MYGN Earnings Date ACHV Earnings Date TKNO Earnings Date VNRX Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Leading Healthcare Provider Stock Soars on Earnings BeatViking Therapeutics: Pharma Stock Soars on Positive EarningsEarnings Season Sell-Off: Is This Tech Giant a Buy?Pharma Leader Beats on Earnings, But Shares FallSemiconductor Giant Posts Big Earnings Beat, but Shares Stay FlatIs This Industrial Stock a Buy After Recent Earnings Boost?Consumer Staple Stock's Q2 Earnings: Key Surprises and Challenges This page (NYSE:NAVB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
